Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In the beauty and wellness business, the timing of TV shopping broadcasts was deferred. In the cosmetics business, early-summer weather was unfavorable and advertising expenses increased. In the sustainable business, delayed deliveries by environmental equipment manufacturers had an impact. Meanwhile, the regenerative medicine-related business benefited from a substantial increase in OEM orders and the full-scale launch of the cell processing business, as well as lower depreciation and amortization and SG&A expenses.
Although the filing states that events or conditions exist that raise substantial doubt about the going-concern assumption, it concludes that no material uncertainty is recognized because measures are being implemented. There are no notes regarding the going-concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥587 million (YoY -2.0%) |
| Operating profit | ¥-130 million |
| Ordinary income | ¥-106 million |
| Profit attributable to owners of the parent | ¥-107 million |
| Net income per share | ¥(1.29) |
| Equity ratio | End of the current fiscal period 81.1 / End of previous period 75.4 |
| Total assets | ¥2,217 million |
| Net assets | ¥1,798 million |
| Cash and cash equivalents at end of period | ¥49,860 thousand |
| Full-year earnings forecast | Net Sales ¥2,863 million (YoY +20.8%) / Operating profit ¥-213 million / Ordinary income ¥-223 million / Net income ¥-246 million |
| Annual Dividend Forecast | ¥0.00 → ¥0.00 |
| Segment revenue | Cosmetics business ¥271,222 thousand / Beauty and wellness business ¥173,882 thousand / Regenerative Medicine-Related Business ¥131,569 thousand / Sustainability Businesses ¥568 thousand / Investment ¥10,354 thousand |
| Segment profit | Cosmetics business ¥-63,781 thousand / Beauty and wellness business ¥-21,509 thousand / Regenerative Medicine-Related Business ¥15,568 thousand / Sustainability Businesses ¥-11,748 thousand / Investment ¥7,779 thousand |
| Depreciation and amortization | ¥2,043 thousand |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income: none (total: —); extraordinary losses: not stated |
| Disclosure regarding the going concern assumption | Although the filing states that events or conditions exist that raise substantial doubt about the going-concern assumption, it concludes that no material uncertainty is recognized because measures are being implemented. There are no notes regarding the going-concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No material changes during the quarter (additions: 0 companies; exclusions: 0 companies) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 82,680,236 shares |
| Treasury Shares at Period-End | 0 shares |
| Factors Behind Changes in Business Performance | In the beauty and wellness business, the timing of TV shopping broadcasts was deferred. In the cosmetics business, early-summer weather was unfavorable and advertising expenses increased. In the sustainable business, delayed deliveries by environmental equipment manufacturers had an impact. Meanwhile, the regenerative medicine-related business benefited from a substantial increase in OEM orders and the full-scale launch of the cell processing business, as well as lower depreciation and amortization and SG&A expenses. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The timing of TV shopping broadcasts was deferred, early-summer weather was unfavorable, and delayed deliveries by environmental equipment manufacturers put downward pressure on sales. Meanwhile, the operating loss narrowed due to increased OEM orders in the regenerative medicine-related business, the full-scale launch of the cell processing business, and lower cost of sales, selling expenses and general and administrative expenses.